1. AHRO : Austin Health Research Online
  2. Austin Health research
  3. Journal articles
Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/32063
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHerbst, Roy S-
dc.contributor.authorWu, Yi-Long-
dc.contributor.authorJohn, Thomas-
dc.contributor.authorGrohe, Christian-
dc.contributor.authorMajem, Margarita-
dc.contributor.authorWang, Jie-
dc.contributor.authorKato, Terufumi-
dc.contributor.authorGoldman, Jonathan W-
dc.contributor.authorLaktionov, Konstantin-
dc.contributor.authorKim, Sang-We-
dc.contributor.authorYu, Chong-Jen-
dc.contributor.authorVu, Huu Vinh-
dc.contributor.authorLu, Shun-
dc.contributor.authorLee, Kye Young-
dc.contributor.authorMukhametshina, Guzel-
dc.contributor.authorAkewanlop, Charuwan-
dc.contributor.authorde Marinis, Filippo-
dc.contributor.authorBonanno, Laura-
dc.contributor.authorDomine, Manuel-
dc.contributor.authorShepherd, Frances A-
dc.contributor.authorUrban, Damien-
dc.contributor.authorHuang, Xiangning-
dc.contributor.authorBolanos, Ana-
dc.contributor.authorStachowiak, Marta-
dc.contributor.authorTsuboi, Masahiro-
dc.date2023-
dc.date.accessioned2023-02-07T05:37:49Z-
dc.date.available2023-02-07T05:37:49Z-
dc.date.issued2023-01-31-
dc.identifier.citationJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 2023; 41(10)en_US
dc.identifier.issn1527-7755-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/32063-
dc.description.abstractThe phase III ADAURA (ClinicalTrials.gov identifier: NCT02511106) primary analysis demonstrated a clinically significant disease-free survival (DFS) benefit with adjuvant osimertinib versus placebo in EGFR-mutated stage IB-IIIA non-small-cell lung cancer (NSCLC) after complete tumor resection (DFS hazard ratio [HR], 0.20 [99.12% CI, 0.14 to 0.30]; P < .001). We report an updated exploratory analysis of final DFS data.en_US
dc.language.isoeng-
dc.titleAdjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleJournal of Clinical oncology: Official Journal of the American Society of Clinical Oncologyen_US
dc.identifier.affiliationMedical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT.en_US
dc.identifier.affiliationGuangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.en_US
dc.identifier.affiliationMedical Oncologyen_US
dc.identifier.affiliationKlinik für Pneumologie-Evangelische Lungenklinik Berlin Buch, Berlin, Germany.en_US
dc.identifier.affiliationDepartment of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.en_US
dc.identifier.affiliationCancer Hospital Chinese Academy of Medical Sciences, Beijing, China.en_US
dc.identifier.affiliationDepartment of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan.en_US
dc.identifier.affiliationDavid Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA.en_US
dc.identifier.affiliationFederal State Budgetary Institution "N.N.Blokhin National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation, Moscow, Russia.en_US
dc.identifier.affiliationDepartment of Oncology, Asan Medical Center, Seoul, South Korea.en_US
dc.identifier.affiliationDepartment of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.en_US
dc.identifier.affiliationDepartment Thoracic Surgery, Cho Ray Hospital, Hochiminh City, Vietnam.en_US
dc.identifier.affiliationDepartment of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.en_US
dc.identifier.affiliationPrecision Medicine Lung Cancer Center, Konkuk University Medical Center, Seoul, South Korea.en_US
dc.identifier.affiliationRepublican Clinical Oncology Center, Kazan, Republic of Tatarstan, Russia.en_US
dc.identifier.affiliationDivision of Medical Oncology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand.en_US
dc.identifier.affiliationThoracic Oncology Division, European Institute of Oncology (IEO), IRCCS, Milan, Italy.en_US
dc.identifier.affiliationMedical Oncology 2, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy.en_US
dc.identifier.affiliationDepartment of Oncology, Hospital Universitario Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain.en_US
dc.identifier.affiliationDepartment of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Center, Toronto, Canada.en_US
dc.identifier.affiliationDepartment of Oncology, Sheba Medical Center, Tel Hashomer, Israel.en_US
dc.identifier.affiliationOncology Biometrics, AstraZeneca, Cambridge, United Kingdom.en_US
dc.identifier.affiliationOncology Research and Development, AstraZeneca, Toronto, Ontario, Canada.en_US
dc.identifier.affiliationLate Oncology Research and Development, AstraZeneca, Warsaw, Poland.en_US
dc.identifier.affiliationDepartment of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa, Japan.en_US
dc.identifier.doi10.1200/JCO.22.02186en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0003-2535-5847en_US
dc.identifier.orcid0000-0002-3611-0258en_US
dc.identifier.orcid0000-0002-5602-0487en_US
dc.identifier.orcid0000-0002-5853-1424en_US
dc.identifier.orcid0000-0002-4925-8243en_US
dc.identifier.orcid0000-0003-4469-502Xen_US
dc.identifier.orcid0000-0001-5664-9392en_US
dc.identifier.orcid0000-0001-6872-2403en_US
dc.identifier.orcid0000-0001-8833-7262en_US
dc.identifier.orcid0000-0003-4687-5593en_US
dc.identifier.orcid0000-0003-1022-3745en_US
dc.identifier.orcid0000-0001-5218-4970en_US
dc.identifier.orcid0000-0002-1128-434Xen_US
dc.identifier.orcid0000-0002-9143-751Xen_US
dc.identifier.orcid0000-0003-3031-5807en_US
dc.identifier.pubmedid36720083-
dc.description.startpageJCO2202186-
local.name.researcherJohn, Thomas
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.languageiso639-1en-
item.cerifentitytypePublications-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

72
checked on Dec 20, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.